It’s a cash flow negative situation when creating your own sales distribution channel. Upfront costs for payback months later. Additional filings now won’t help with the cash flow crunch coming after Lannett deal terminates. Those are next near benefits, if FDA approval process is smooth.
If they could have they would have sone it themselves. But they cant. They will seek out another bum company to work with and further sink shareholder value. Thats the way of the Rat!
News 
Market Data 
Discover 
